Programmed cell death protein 1: Difference between revisions
CSV import |
CSV import |
||
| Line 29: | Line 29: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
<gallery> | |||
File:Negative,_low_and_high_PD-L1_expression_by_immunohistochemistry.png | |||
</gallery> | |||
Latest revision as of 02:09, 17 February 2025
Programmed cell death protein 1 (also known as PD-1 and CD279 (cluster of differentiation 279)) is a protein that in humans is encoded by the PDCD1 gene. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. It functions as an immune checkpoint and plays a major role in down regulating the immune system by preventing the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells).
Function[edit]
PD-1 is an immune checkpoint receptor that is expressed on the surface of activated T cells, B cells, and myeloid cells. The primary function of PD-1 is to limit the activity of T cells in peripheral tissues during an inflammatory response to infection and to limit autoimmunity.
Clinical significance[edit]
PD-1 and its ligands, PD-L1 and PD-L2, are often upregulated in cancer cells and the surrounding microenvironment. This upregulation often leads to the inhibition of T cells that would otherwise recognize and destroy cancer cells. Inhibition of PD-1 or its ligands can restore the cytotoxic activity of T cells against cancer cells, providing the basis for the development of PD-1 inhibitors as cancer therapeutics.
PD-1 inhibitors[edit]
PD-1 inhibitors are a type of immunotherapy that block the interaction between PD-1 and its ligands, thereby enhancing the immune system's anti-tumor response. These drugs have shown significant clinical benefits in the treatment of a variety of cancers, including melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, and head and neck cancers.
See also[edit]
References[edit]
<references />
